Skip to main content
Qiagen N.V. logo

Qiagen N.V. — Investor Relations & Filings

Ticker · QIA ISIN · NL0015001WM6 LEI · 54930036WK3GMCN17Z57 F Manufacturing
Open in API
Filings indexed 627 across all filing types
Latest filing 2007-06-06 Merger & Acquisition
Country NL Netherlands
Listing F QIA

About Qiagen N.V.

https://www.qiagen.com/

Qiagen N.V. is a global provider of "Sample to Insight" solutions, offering technologies that transform biological materials into valuable molecular insights. The company develops and markets sample and assay technologies, automated instrumentation, and bioinformatics software for molecular diagnostics, applied testing, academic research, and pharmaceutical development. Its comprehensive portfolio supports the entire workflow from sample collection and preparation of DNA, RNA, and proteins to analysis and interpretation. Key product areas include sample preparation kits, PCR, digital PCR (dPCR), and next-generation sequencing (NGS) solutions, as well as syndromic testing panels for infectious diseases.

Recent filings

Filing Released Lang Actions
424(B)(3)
Merger & Acquisition Classification · 100% confidence The document is a detailed proxy statement/prospectus related to a special meeting of shareholders to approve a merger agreement between eGene, Inc. and QIAGEN North American Holdings, Inc. It includes voting instructions, meeting details, merger terms, and extensive information about the merger and related agreements. The document is not a simple announcement but a comprehensive solicitation of shareholder votes with detailed merger information, typical of a proxy statement related to a merger transaction. This fits the category of Merger & Acquisition filings, which include merger communications and proxy statements related to mergers.
2007-06-06 English
FORM 4
Director's Dealing
2007-06-06 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is a letter from QIAGEN N.V. to the SEC requesting acceleration of the effectiveness of a Registration Statement on Form F-4. It references the filing date and file number, and requests the SEC to declare the filing effective earlier than scheduled. The document is short (2092 characters) and is a formal request related to a regulatory filing process, not the filing itself or a report containing financial data. It does not contain financial statements or substantive financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and filings that do not fit other categories.
2007-06-04 English
FORM 4
Director's Dealing
2007-06-04 English
FORM 6-K
M&A Activity Classification · 95% confidence The document is a Form 6-K filed with the SEC by QIAGEN N.V., a foreign private issuer, dated June 3, 2007. It contains a press release and merger agreement exhibits announcing a definitive agreement to merge with Digene Corp. The content focuses on the merger transaction details, strategic rationale, expected financial impact, and integration plans. There are no financial statements or detailed financial performance data typical of annual or interim reports. The document is primarily an announcement of a merger transaction and related agreements, not a full merger proxy statement or tender offer filing. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2007-06-04 English
AMENDMENT NO. 1 TO FORM F-4
Merger & Acquisition Classification · 100% confidence The document is an Amendment No. 1 to Form F-4, a registration statement filed with the SEC under the Securities Act of 1933. It relates to a merger transaction involving QIAGEN N.V. and eGene, Inc. The text includes a proxy statement/prospectus for a special shareholders meeting to approve the merger agreement. It contains detailed information about the merger, voting instructions, risk factors, financial data, and annexes including the merger agreement and voting agreements. This type of filing is a merger-related registration statement and proxy solicitation document, which is best classified under Merger & Acquisition filings (MA) rather than a general proxy solicitation (PSI) because it is a Form F-4 amendment specifically related to a merger transaction and includes detailed merger documentation and disclosures. The document is substantive and lengthy (15,000 characters), not merely an announcement or notice. Therefore, the appropriate classification is Merger & Acquisition (MA).
2007-05-31 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.